232 related articles for article (PubMed ID: 26675495)
1. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
Beck JT
Onco Targets Ther; 2015; 8():3629-38. PubMed ID: 26675495
[TBL] [Abstract][Full Text] [Related]
2. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Jerusalem G; Rorive A; Collignon J
Breast Cancer (Dove Med Press); 2014; 6():43-57. PubMed ID: 24833916
[TBL] [Abstract][Full Text] [Related]
3. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.
Arena F
Cancer Manag Res; 2014; 6():389-95. PubMed ID: 25336989
[TBL] [Abstract][Full Text] [Related]
5. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
Ng VC; Johnson JJ; Cuellar S
J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
[TBL] [Abstract][Full Text] [Related]
6. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.
Gnant M; Greil R; Hubalek M; Steger G
Breast Care (Basel); 2013 Aug; 8(4):293-9. PubMed ID: 24415983
[TBL] [Abstract][Full Text] [Related]
8. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
[TBL] [Abstract][Full Text] [Related]
9. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
10. A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
Beck JT; Mantooth R
Case Rep Oncol; 2015; 8(1):101-5. PubMed ID: 25848360
[TBL] [Abstract][Full Text] [Related]
11. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM
Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
[TBL] [Abstract][Full Text] [Related]
12. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.
Saksena R; Wong ST
Breast Cancer (Dove Med Press); 2013; 5():27-35. PubMed ID: 24648755
[TBL] [Abstract][Full Text] [Related]
14. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
16. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.
Sobhani N; Generali D; Zanconati F; Bortul M; Scaggiante B
World J Clin Oncol; 2018 Dec; 9(8):172-179. PubMed ID: 30622925
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
Reinert T; Barrios CH
Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
Beith J; Burslem K; Bell R; Woodward N; McCarthy N; De Boer R; Loi S; Redfern A
Asia Pac J Clin Oncol; 2016 Mar; 12 Suppl 1():3-18. PubMed ID: 27001208
[TBL] [Abstract][Full Text] [Related]
19. Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.
Yardley DA
Breast Cancer (Auckl); 2013; 7():7-22. PubMed ID: 23492649
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
Yi Z; Ma F
J Breast Cancer; 2017 Dec; 20(4):321-326. PubMed ID: 29285035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
